Beta Drugs Limited has informed the Exchange about General Updates
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beta Drugs Limited has submitted a clarification to NSE regarding observations on the Corrigendum to its Extra Ordinary General Meeting notice dated 9th January 2026. The company provided a detailed table showing 33 proposed allottees under a preferential issue, with the number of equity shares to be allotted and their percentage of post-preferential offer capital. The largest allottee is Anjali Ajit Deval receiving 1,25,596 shares (1.13%), followed by Kayadam Ramanathan Bharat with 47,181 shares (0.43%), while most other allottees receive less than 1,000 shares each. The clarification was submitted in response to NSE's letter dated 19th March 2026, and was signed by Company Secretary Rajni Brar on 20th March 2026.
This is a procedural clarification to the stock exchange with no new business action — the preferential allotment structure remains as previously disclosed, so there is no immediate material impact on shareholders or the stock price.